IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced that the first patient has been enrolled in its Phase 1 clinical trial evaluating IDE892, an ...
Please provide your email address to receive an email when new articles are posted on . Surveillance of patients carrying the CDKN2A gene mutation led to earlier detection of pancreatic ductal ...
Study of BRAF mutations in melanoma and nevi from patients with germline mutation in the CDKN2A gene
Predicting survival and metastasis in soft tissue sarcoma: A gene microarray study using RNA derived from archival paraffin-embedded tumours No significant financial relationships to disclose. This is ...
Telomir Pharmaceuticals (TELO) announced new preclinical cancer data showing that Telomir-1 reverses DNA methylation of CDKN2A, a master tumor suppressor gene silenced in many aggressive cancers.
Cellular senescence contributes to IPF progression by promoting inflammation and disrupting immune homeostasis. Four key genes—CDKN2A, VEGFA, SOX2, and FOXO3—were identified as differentially ...
Pancreatic cancer surveillance in high-risk individuals may lead to detection of pancreatic ductal adenocarcinoma (PDAC) at an earlier stage and with improved survival. This study evaluated the yield ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results